Medexus Pharmaceuticals Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
58410Q203
SEDOL
N/A
CIK
N/A
www.medexus.com
LEI:
FIGI: BBG0029BPQV2
MDP
Medexus Pharmaceuticals Inc.
GICS: - · Sector: - · Sub-Sector: Drug Manufacturers—Specialty & Generic
AI
PROFILER
NAME
Medexus Pharmaceuticals Inc.
ISIN
CA58410Q2036
TICKER
MDP
MIC
XTSE
REUTERS
MDP.TO
BLOOMBERG
MDP CN
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by Newsfile Corp.

Tue, 04.02.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Progra...
Read More
Medexus Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Fri, 31.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and ...
Read More
Medexus Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Fri, 31.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offe...
Read More
Medexus Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Wed, 22.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 22, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the succe...
Read More
Medexus Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Wed, 15.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv...
Read More
Medexus Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S